PT - JOURNAL ARTICLE AU - Randall J. Olsen AU - Paul A. Christensen AU - S. Wesley Long AU - Sishir Subedi AU - Parsa Hodjat AU - Robert Olson AU - Marcus Nguyen AU - James J. Davis AU - Prasanti Yerramilli AU - Matthew Ojeda Saavedra AU - Layne Pruitt AU - Kristina Reppond AU - Madison N. Shyer AU - Jessica Cambric AU - Ryan Gadd AU - Rashi M. Thakur AU - Akanksha Batajoo AU - Ilya J. Finkelstein AU - Jimmy Gollihar AU - James M. Musser TI - Trajectory of Growth of SARS-CoV-2 Variants in Houston, Texas, January through May 2021 Based on 12,476 Genome Sequences AID - 10.1101/2021.05.20.21257552 DP - 2021 Jan 01 TA - medRxiv PG - 2021.05.20.21257552 4099 - http://medrxiv.org/content/early/2021/06/12/2021.05.20.21257552.short 4100 - http://medrxiv.org/content/early/2021/06/12/2021.05.20.21257552.full AB - Genetic variants of the SARS-CoV-2 virus are of substantial concern because they can detrimentally alter the pandemic course and disease features in individual patients. Here we report SARS-CoV-2 genome sequences from 12,476 patients in the Houston Methodist healthcare system diagnosed from January 1, 2021 through May 31, 2021. The SARS-CoV-2 variant designated U.K. B.1.1.7 increased rapidly and caused 63%-90% of all new cases in the Houston area in the latter half of May. Eleven of the 3,276 B.1.1.7 genomes had an E484K change in spike protein. Compared with non-B.1.1.7 patients, individuals with B.1.1.7 had a significantly lower cycle threshold value (a proxy for higher virus load) and significantly higher rate of hospitalization. Other variants (e.g., B.1.429, B.1.427, P.1, P.2, and R.1) also increased rapidly, although the magnitude was less than for B.1.1.7. We identified 22 patients infected with B.1.617 “India” variants; these patients had a high rate of hospitalization. Vaccine breakthrough cases (n=207) were caused by a heterogeneous array of virus genotypes, including many that are not variants of interest or concern. In the aggregate, our study delineates the trajectory of concerning SARS-CoV-2 variants circulating in a major metropolitan area, documents B.1.1.7 as the major cause of new cases in Houston, and heralds the arrival and spread of B.1.617 variants in the metroplex.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe are indebted to Drs. Marc Boom and Dirk Sostman for their support, to generous Houston philanthropists for their support and to the Houston Methodist Academic Institute Infectious Diseases Fund that have made this ongoing project possible. James J. Davis and Robert Olson were funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. 75N93019C00076.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The work was approved by the Houston Methodist Research Institute Institutional Review Board (IRB1010-0199)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll genomes have been submitted to GISAID (www.gisaid.org) https://www.gisaid.org